06 Jun 2021

Refusal trends of recommended therapies for Glioblastoma Multiforme | Submitted

Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the brain with a dismal prognosis. Approximately 30.9% of these primary brain tumors are malignant, with GBM being the most commonly identified malignant histology with an annual-age adjusted incidence rate of 14.7%. The annual age-adjusted incidence for GBM among persons age above 40 years is 3.21 per 100,000 population. Further, lack of effective therapies lead to inevitable relapse and approximately 70% of the patients die with in first 2 years of diagnosis. Of all the malignant brain tumors, GBM has the worst prognosis with five-year survival of 5.6%.

In majority of cases, treatment recommendations are based on the patient’s current performance status, molecular profile and sub-type of GBM. Yet, patients may refuse all or parts of the recommended treatment. In malignancies including head and neck, lung, and pancreatic cancers – subsets that refused treatments have been identified to be greater than 80 years old, of African American descent, carrying non-private insurance, and presence of increased number of comorbidities as predictors of refusing recommended therapies. Using a national database for patients with newly diagnosed GBM, this study is focusing on assessing the patterns of denying recommended treatments and its impact on the outcomes.

Comments Off on Refusal trends of recommended therapies for Glioblastoma Multiforme | Submitted